The Role of TP-R on Alcohol-Induced Multi-Organ Damage: Liver and Heart

TP-R 在酒精引起的多器官损伤中的作用:肝脏和心脏

基本信息

项目摘要

It is well-established that liver is the primary target of ethanol action and alcohol-associated liver disease (AALD) is a major health concern in general population. It should also be noted that the incidence of heart disease due to chronic alcohol consumption continues to rise owing to the increased chronic alcohol drinking habits among humans. It is becoming increasingly evident that a strong positive correlation exists between alcohol-associated liver injury (AALD) and alcoholic cardiomyopathy (ACM). It has recently become clear that the combination of obesity with heavy drinking exacerbates ethanol-induced organ injury. Thus, there is an urgent need to define mechanisms by which obesity and alcohol either individually or in combination, promote liver and cardiac injury. Central to our hypothesis is that thromboxane-prostanoid receptor (TP-R) is a common link between AALD and ACM. TP-R is a G-protein coupled receptor, expressed in all tissues, and is activated by thromboxane A2 as well as isoprostanes, eicosanoids mediating inflammatory response and oxidative stress. TP-R is known to play a role in the pathophysiology of several chronic inflammatory diseases, such as cardiovascular disease and certain autoimmune diseases. Little is known, however about a role for TP-R in modulating obesity and alcohol-related disorders. We present exciting preliminary data in this proposal that ethanol-induced hepatic inflammation is greatly attenuated in TP-R-KO mice. Interestingly, our preliminary data also show that TP-R expression is significantly higher in human peripheral blood mononuclear cells (PBMCs) collected from patients with obesity or CVD compared to control subjects and therefore, its involvement in both AALD and ACM might be important, and present opportunities for treatment. Based on previous reports and our preliminary data, we hypothesize that in the presence of obesity, chronic alcohol consumption promotes liver and cardiac injury and this effect is mediated at least in part, via activation of TP-R through its effects on inflammation and oxidative stress. We will use nutritional, genetic, and molecular approaches to determine the role of TP-R in altering AALD and ACM. In Aim 1, we will define the role of hepatocyte-TP-R in modulating ethanol- and/or obesity- induced liver injury and cardiomyopathy in mice. In Aim 2, we will assess the role of cardiomyocyte- TP-R in modulating ethanol- and/or obesity-induced liver injury and cardiomyopathy in mice. Overall, the proposed research will uncover the role of TP-R in modulating AALD and ACM in the presence or absence of obesity, to identify potential mechanisms, and to set the stage for the development of effective therapeutic agents for human patients affected by the metabolic complications of obesity and/or excess ethanol consumption.
公认的是肝脏是乙醇作用和与酒精相关的肝脏的主要目标 疾病(AALD)是普通人群的主要健康问题。还应注意的是 由于长期饮酒引起的心脏病的发病率不断增加 增加了人类慢性酒精饮酒习惯。越来越明显的是 酒精相关的肝损伤(AALD)和酒精饮料之间存在很强的正相关 心肌病(ACM)。最近很明显,肥胖与沉重的结合 饮酒加剧了乙醇引起的器官损伤。因此,迫切需要定义 肥胖和酒精单独或结合起来的机制,促进肝脏和 心脏损伤。我们假设的核心是血栓烷 - 螺旋体螺旋体受体(TP-R)是一个 AALD和ACM之间的共同链接。 TP-R是G蛋白偶联受体,在所有人中表达 组织,并被血栓烷A2和异前列腺激活,eicosanoids介导 炎症反应和氧化应激。众所周知,TP-R在病理生理中起作用 几种慢性炎症性疾病,例如心血管疾病和某些自身免疫性 疾病。鲜为人知,但是TP-R在调节肥胖和酒精有关的角色中的作用 疾病。我们在此提案中介绍了令人兴奋的初步数据,即乙醇引起的肝 在TP-R-KO小鼠中,炎症大大减弱。有趣的是,我们的初步数据也显示 在人外周血单核细胞(PBMC)中,TP-R表达显着更高 与对照受试者相比,从肥胖或CVD患者中收集 参与AALD和ACM可能很重要,并且是治疗的机会。 根据以前的报告和我们的初步数据,我们假设在肥胖存在的情况下, 长期饮酒会促进肝脏和心脏损伤,至少在 部分,通过对TP-R的激活对炎症和氧化应激的影响。我们将使用 营养,遗传和分子方法,以确定TP-R在改变AALD和的作用 ACM。在AIM 1中,我们将定义肝细胞-TP-R在调节乙醇和/或肥胖症中的作用。 小鼠诱导肝损伤和心肌病。在AIM 2中,我们将评估心肌细胞的作用 TP-R在调节小鼠的乙醇和/或肥胖诱导的肝损伤和心肌病中。全面的, 拟议的研究将发现TP-R在存在下调节AALD和ACM中的作用 或缺乏肥胖,确定潜在机制,并为发展奠定了基础 受肥胖代谢并发症影响的人类患者的有效治疗剂 和/或过量的乙醇消耗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Saraswathi Viswanathan其他文献

Saraswathi Viswanathan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Saraswathi Viswanathan', 18)}}的其他基金

The Effectiveness of NanoSOD in Ameliorating Ethanol-induced Liver Injury in Obesity
NanoSOD 在改善肥胖者乙醇引起的肝损伤方面的功效
  • 批准号:
    9388032
  • 财政年份:
    2017
  • 资助金额:
    $ 24.18万
  • 项目类别:
Project 10 - The role of nanoformulated Cu/ZnSOD in reducing systemic hypertensi
项目 10 - 纳米配方 Cu/ZnSOD 在降低全身性高血压中的作用
  • 批准号:
    8730202
  • 财政年份:
  • 资助金额:
    $ 24.18万
  • 项目类别:
Project 10 - The role of nanoformulated Cu/ZnSOD in reducing systemic hypertensi
项目 10 - 纳米配方 Cu/ZnSOD 在降低全身性高血压中的作用
  • 批准号:
    8601985
  • 财政年份:
  • 资助金额:
    $ 24.18万
  • 项目类别:

相似国自然基金

饮酒刺激肝细胞分泌外泌体对股骨头内H型血管的影响及分子机制
  • 批准号:
    82272508
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
不同饮酒模式下CD11b+Ly6Chigh细胞群的分化及其对酒精性肝损伤的调控机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
不同饮酒模式下CD11b+Ly6Chigh细胞群的分化及其对酒精性肝损伤的调控机制研究
  • 批准号:
    82200656
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
定量设定法定最低饮酒年龄的方法研究
  • 批准号:
    82103950
  • 批准年份:
    2021
  • 资助金额:
    24.00 万元
  • 项目类别:
    青年科学基金项目
伏隔核多巴胺信号通过调节D1R-、D2R-MSNs活动影响个体差异饮酒行为的机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Identifying the Effects of Race-Related Stressors on Laboratory- Induced Stress and Craving among African Americans with Alcohol Use Disorder
确定种族相关压力源对患有酒精使用障碍的非裔美国人实验室诱发的压力和渴望的影响
  • 批准号:
    10664454
  • 财政年份:
    2023
  • 资助金额:
    $ 24.18万
  • 项目类别:
PPARdelta receptors and alcohol use phenotypes
PPARδ 受体和饮酒表型
  • 批准号:
    10682348
  • 财政年份:
    2023
  • 资助金额:
    $ 24.18万
  • 项目类别:
The Robert T. Malison Yale-Chulalongkorn Stress, Alcohol Use and Psychopathology Training Program
罗伯特·T·马利森耶鲁-朱拉隆功压力、酒精使用和精神病理学培训计划
  • 批准号:
    10665205
  • 财政年份:
    2023
  • 资助金额:
    $ 24.18万
  • 项目类别:
Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults
预防太平洋岛民年轻人的酒精使用障碍和酒精相关危害
  • 批准号:
    10804296
  • 财政年份:
    2023
  • 资助金额:
    $ 24.18万
  • 项目类别:
A Peer Recovery Coaching Intervention for Hospitalized Alcohol Use Disorder Patients
针对住院酒精使用障碍患者的同伴恢复辅导干预
  • 批准号:
    10803885
  • 财政年份:
    2023
  • 资助金额:
    $ 24.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了